Clinical Trials Logo

Clinical Trial Summary

The three-year cumulative risk of a recurrent stroke, dependent on aetiology, is up to 25 per cent. At present, preventing recurrence relies on a broad approach to reduce risk factors associated with atherosclerosis, heart disease and metabolic disorders. However, more specific interventions, such as anticoagulation and surgery or stenting, need aetiologic information. BIOSIGNAL aims to determine where the most promising biomarkers can help identify stroke aetiology and also predict recurrent stroke. In addition, the insights gained into the processes underlying different stroke subtypes may lead to more targeted diagnostic tools.


Clinical Trial Description

Objectives and specific aims:

The investigators propose to prospectively evaluate the predictive value of the most promising blood biomarkers to identify treatable stroke etiologies on admission and risk of recurrence in 3000 consecutive ischemic stroke patients enrolled by 10 centers in Europe and the US.

The clinical endpoints of the study are 1) recurrent stroke within one year, 2) all types of atrial fibrillation (AF) detected on admission or by prolonged ambulatory cardiac rhythm monitors, 3) presence of cerebrovascular atherosclerosis detected by ultrasound investigations and 4) new silent ischemic brain lesions and progression of chronic cerebral ischemic lesion volume detected by repeated magnetic resonance imaging (MRI and MRA) and (i.e. on admission and after 12 months).

Aim 1: To determine whether the proposed biomarkers independently predict recurrent stroke among all patients. Hypothesis 1: Elevated levels of one or more of the proposed biomarkers will independently predict recurrent strokes during trial follow-up, assessed by structured interviews, as well as chart reviews 90 days and 1 year after the index stroke.

Aim 2: To determine whether cardioembolic (CE) biomarkers are associated with atrial fibrillation among all patients. Hypothesis 2: Baseline values of one or more of the proposed CE biomarkers will be independently associated with AF, including history of AF, AF detection at baseline, or AF detected during the follow up period by prolonged ambulatory cardiac rhythm monitors and structured interviews as well as chart reviews 90 days and 1 year after the index stroke.

Aim 3: To determine whether large artery atherosclerosis (LAA) biomarkers are associated with a) the presence of cerebrovascular atherosclerosis among all patients. Hypothesis 3: Baseline values of one or more of the proposed LAA biomarkers will be independently associated with the presence of extra and intracranial atherosclerosis among patients with ischemic stroke, assessed by duplex sonography.

Exploratory Aim 4: To determine whether the proposed biomarkers will predict b) new silent strokes and c) progression of chronic cerebral ischemic lesion (white matter hyper-intensity) volume (WMHV) among cryptogenic stroke patients. Hypothesis 4: Baseline values of one or more of the proposed biomarkers will independently predict a) silent stroke b) progression of WMHV, during study follow-up, assessed by repeated magnetic resonance imaging (MRI) (on admission, and 1 year after the index stroke).

This study will be conducted in compliance with the protocol, the current version of the Declaration of Helsinki, and Good Clinical Practice (GCP) guidelines as well as all national legal and regulatory requirements. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02274727
Study type Observational
Source University of Zurich
Contact
Status Active, not recruiting
Phase
Start date September 2014
Completion date October 2018

See also
  Status Clinical Trial Phase
Recruiting NCT03633422 - Evaluation of Stroke Patient Screening
Recruiting NCT03679637 - Tablet-based Aphasia Therapy in the Acute Phase After Stroke N/A
Recruiting NCT03132558 - Contrast Induced Acute Kidney in Patients With Acute Stroke N/A
Recruiting NCT02541578 - Physiological Complexity of Gait Over the First Six Months Post Stroke N/A
Recruiting NCT02893631 - Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
Recruiting NCT02225730 - Imaging Collaterals in Acute Stroke (iCAS) N/A
Terminated NCT01705353 - The Role of HMGB-1 in Chronic Stroke N/A
Active, not recruiting NCT01581502 - SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF) N/A
Completed NCT01182818 - Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease N/A
Completed NCT00761982 - Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment. Phase 1/Phase 2
Completed NCT00535197 - Autologous Bone Marrow Stem Cells in Ischemic Stroke. Phase 1/Phase 2
Terminated NCT00132509 - FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke Phase 2
Recruiting NCT03235271 - Pilot Study of Acute Stroke Using the Brainpulseâ„¢
Not yet recruiting NCT03574038 - Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke N/A
Not yet recruiting NCT03592563 - CUHK Brain Health Longitudinal Study
Recruiting NCT03634748 - Thrombolysis in stRoke With Unknown onSet Based on noncontrasT CT
Recruiting NCT03324321 - Feasibility of Improving Cerebral Autoregulation in Acute Intracerebral Haemorrhage N/A
Not yet recruiting NCT03641963 - aICP Measurement in Patients With Cerebral Artery Infarction / aICP MCA Infarction N/A
Recruiting NCT02989376 - Carotid Duplex Ultrasound for Selecting Patients for Endovascular Thrombectomy in Acute Stroke Patients N/A
Recruiting NCT02207023 - Healthy Lifestyles After Stroke N/A